# Clinical Study of U32 in Patients With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct07036250/  
OnCo record `nct07036250` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of U32 CAR-T in acute myeloid leukaemia, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.

## Summary

Clinical Study of U32 in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT07036250 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 20 participants planned, started 2025-07-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: U32 CAR-T.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07036250
- Phase: 1/2
- Setting: A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.
- Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07036250: https://clinicaltrials.gov/study/NCT07036250

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)

---
JSON: https://onco.cc/api/v1/entities/nct07036250.json